Clinical Research Directory

Inclusion Criteria: * Willing to consent and to follow study procedures * 18 years of age or above at time of screening; both sexes eligible * Diagnosed with CML-CP and was intolerant to or failed from at least 3 TKI treatments * ECOG score \>= 2 * Adequate hematological indicators and have not used blood products or Colony-Stimulating Factor (CSF) * Adequate kidney, liver and coagulation function * Adequate QTc interval as confirmed by electrocardiogram (ECG) test * Negative pregnancy result at screening for female patients of child-bearing potential * Willing to take contraceptive measure during the study (For male and female patients of child-bearing potential) Exclusion Criteria: * Reception of TKI treatment or other anti-tumor treatments prior to first dose * History or presence of extramedullary leukemia * History of progression to CML-AP or BP * Presence or having uncontrolled condition for cardiovascular diseases * History of severe hemorrhagic disease * Presence of malabsorption or other conditions that may affect drug absorption * History of other primary malignancy within 5 years * Presence of continuous or active infection (including HIV, hepatitis B, hepatitis C) * In need for or having long-term immune suppressive treatment * Reception of major surgery 28 days before first dose * Presence of unrecovered toxicity due to anti-tumor treatment with CTCAE grade \>=1 * Presence of other conditions that the investigators or medical monitor deem unfit for the study